Baxter International Inc. (NYSE:BAX) – Stock analysts at Leerink Swann increased their Q2 2018 EPS estimates for Baxter International in a research note issued to investors on Tuesday. Leerink Swann analyst D. Antalffy now forecasts that the firm will post earnings of $0.57 per share for the quarter, up from their prior forecast of $0.55. Leerink Swann also issued estimates for Baxter International’s FY2020 earnings at $2.94 EPS.
Baxter International (NYSE:BAX) last released its quarterly earnings results on Tuesday, July 26th. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.06. The company had revenue of $2.60 billion for the quarter, compared to analyst estimates of $2.51 billion. Baxter International had a net margin of 47.74% and a return on equity of 10.70%. The firm’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business earned $1.00 earnings per share.
BAX has been the subject of several other research reports. JPMorgan Chase & Co. upped their target price on shares of Baxter International from $45.00 to $48.00 and gave the company a “neutral” rating in a report on Wednesday, July 27th. RBC Capital Markets restated a “hold” rating and issued a $50.00 target price (up previously from $47.00) on shares of Baxter International in a report on Wednesday, July 27th. Zacks Investment Research cut shares of Baxter International from a “hold” rating to a “sell” rating in a report on Tuesday, July 19th. Goldman Sachs Group Inc. restated a “buy” rating on shares of Baxter International in a report on Wednesday, July 6th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $60.00 target price on shares of Baxter International in a report on Monday, June 13th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $48.25.
Baxter International (NYSE:BAX) traded down 2.09% during mid-day trading on Thursday, reaching $46.92. 3,309,909 shares of the company traded hands. The stock’s 50 day moving average price is $47.21 and its 200 day moving average price is $45.01. The firm has a market capitalization of $25.52 billion, a price-to-earnings ratio of 5.39 and a beta of 0.64. Baxter International has a 52 week low of $32.18 and a 52 week high of $49.49.
Large investors have recently added to or reduced their stakes in the company. Trust Department MB Financial Bank N A boosted its stake in Baxter International by 4.1% in the second quarter. Trust Department MB Financial Bank N A now owns 1,746 shares of the company’s stock valued at $122,000 after buying an additional 68 shares in the last quarter. Balentine LLC boosted its stake in Baxter International by 12.6% in the second quarter. Balentine LLC now owns 3,176 shares of the company’s stock valued at $144,000 after buying an additional 356 shares in the last quarter. Checchi Capital Advisers LLC boosted its stake in Baxter International by 1.9% in the second quarter. Checchi Capital Advisers LLC now owns 4,333 shares of the company’s stock valued at $196,000 after buying an additional 81 shares in the last quarter. Pioneer Trust Bank N A OR purchased a new stake in Baxter International during the second quarter valued at about $203,000. Finally, Cobblestone Capital Advisors LLC NY purchased a new stake in Baxter International during the second quarter valued at about $203,000. 84.79% of the stock is currently owned by institutional investors.
The company also recently declared a quarterly dividend, which will be paid on Monday, October 3rd. Shareholders of record on Friday, September 2nd will be paid a dividend of $0.13 per share. The ex-dividend date is Wednesday, August 31st. This represents a $0.52 annualized dividend and a dividend yield of 1.11%. Baxter International’s dividend payout ratio is currently 5.99%.
About Baxter International
Baxter International Inc, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.